22 February 2024 11:00
GMT
Transaction by Person
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company)
announced that, on 20 February 2024, an award of the Company's
ordinary shares of $0.25 each (Ordinary Shares) under the
AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot,
Executive Director and Chief Executive Officer.
The AZIP award was granted on 24
March 2016 and was subject to a four-year performance period
followed by a four-year holding period before vesting. Application
of the performance measures specified at the time of grant resulted
in 50% of the AZIP award entering the holding period.
Following the reinvestment of
dividends accrued during the performance and holding periods and
the withholding of shares to satisfy certain tax obligations
arising on vesting, Mr Soriot acquired Ordinary Shares as detailed
in the table below:
PDMR
|
Ordinary Shares acquired
under the AZIP
|
Pascal Soriot
|
12,345
|
For tax purposes, the fair market value of an
Ordinary Share at vest was 10,418 pence, being the
closing price on the last trading day preceding the
vesting.
Further details are set out in the attached
notification, made in accordance with the requirements of the EU
Market Abuse Regulation (since it forms part of UK law pursuant to
the European Union (Withdrawal) Act 2018).
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Pascal Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Executive Officer
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares
pursuant to a vesting under the AstraZeneca Investment Plan, for
nil consideration.
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
12,345
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
e)
|
Date of the transaction
|
20 February 2024
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC